• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

byConstance Wu
April 20, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma.

2. Lenvatinib plus pembrolizumab demonstrated longer progression-free survival compared to sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The standard treatment of advanced renal cell carcinoma (RCC) has been antagonism of vascular endothelial growth factor (VEGF) with tyrosine kinase inhibitors such as sunitinib. Lenvatinib, an antiangiogenic agent, and pembrolizumab, an anti-programmed cell death 1 monoclonal antibody, have been explored in previous studies as monotherapies for RCC. As such, this study reported the efficacy and safety of lenvatinib plus pembrolizumab treatment compared to sunitinib in patients with advanced RCC. The study determined pembrolizumab plus lenvatinib treated patients had superior progression-free survival and overall survival compared to sunitinib. The most common adverse event was diarrhea, which was greater in the combination therapy group. There was more drug discontinuation in the lenvatinib and pembrolizumab group compared to the lenvatinib and everolimus group or the sunitinib group. One limitation is that patients and investigators were aware of the treatment assignments. Overall, this trial demonstrated that lenvatinib and immune-checkpoint inhibition with pembrolizumab showed superior survival compared to sunitinib alone.

Click here to read the study in the NEJM

Relevant Reading: Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

In-Depth [randomized controlled trial]: This was a multicenter, randomized, open-label trial of 1,069 patients from 200 sites in 20 countries. Patients 18 years of age or older with advanced renal carcinoma, and no prior systemic therapy were included in the study. Patients were excluded from the study if there was not adequate blood pressures control or organ function. Patients were randomized in a 1:1:1 ratio into lenvatinib and pembrolizumab, lenvatinib and everolimus, or sunitinib, respectively. Everolimus and lenvatinib treatment (median, 14.7 months) had significantly longer progression-free survival compared to sunitinib (median, 9.2 months) (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.53 to 0.80; P < 0.001). However, the overall survival between both groups was not significant (HR, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Pembrolizumab and lenvatinib was superior in both progression-free survival (treatment median, 23.9 months; control median, 9.2 months; HR, 0.39; 95% CI, 0.32 to 0.49; P < 0.001) and overall survival (HR, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) when compared to sunitinib. Grade 3 or higher adverse events was observed in 82.4% of the lenvatinib plus pembrolizumab group, 83.1% of the lenvatinib plus everolimus group, and 71.8% of the patients who received sunitinib. In general, this trial demonstrated the use of an immune checkpoint inhibitor is an important treatment component for advanced RCC in combination with standard VEGF inhibition.

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancerkidneylenvatinibpdl-1PembrolizumabRCCrenalrenal cell neoplasmrenal-cell carcinomaVEGF
Previous Post

Comparative efficacy of psychotherapies for reducing self-harm and suicidality in young individuals shows inconsistent and low-quality evidence

Next Post

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
AI Roundup

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

May 28, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Billy Joel’s Brain Condition, Gigi Robinson’s Surgical Advocacy, Climate and Cancer Risk, and West Nile Virus Reaches the United Kingdom

May 27, 2025
Next Post
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Use of bamlanivimab for patients with mild to moderate COVID-19 infection

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

Immunovirotherapy showed acceptable adverse-event profile in pediatric high-grade gliomas

Parents often unaware of adolescents’ suicidal thoughts

Psilocybin does not significantly improve depressive scores compared to escitalopram

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.